Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience

Abstract

In this largest real-life pediatric cohort to date, tofacitinib was effective in at least 16% of patients with highly refractory UC by week 8. Adverse events were minor and largely consistent with adult data.